Fubotv earnings beat by $0.10, revenue topped estimates
On Monday, Stifel analysts began coverage of NewAmsterdam Pharma Co NV (NASDAQ: NAMS), issuing a Buy rating and setting a price target of $44.00 for the company’s shares. Currently trading at $20.16, the stock has attracted strong analyst interest, with consensus targets ranging from $37.11 to $52.68. InvestingPro data reveals several promising indicators, with 5 analysts recently revising their earnings expectations upward. The Stifel team highlighted NewAmsterdam’s position as a distinctive late-stage pharmaceutical company focused on cardiovascular treatments, with a projected timeline for regulatory filings in the second half of 2025 or the first half of 2026.
The analysts underscored the potential of NewAmsterdam’s leading drug candidate, obicetrapib, in the growing lipid-lowering market. They anticipate that the drug’s outcomes from the PREVAIL trial, expected around the end of 2026 or early 2027, could significantly set it apart from competitors. Despite historical setbacks in the drug’s mechanism of action within the pharmaceutical industry, Stifel’s analysis suggests that obicetrapib and the PREVAIL study are fundamentally different and have a high probability of demonstrating a substantial relative risk reduction.
Stifel’s coverage notes that, even with conservative commercial projections, there exists considerable room for the stock’s value to increase. They believe that the risk of a downside surprise is very low, citing obicetrapib’s safety profile and the management team’s track record as reasons for confidence in the successful execution of the PREVAIL trial. The analysts also mention that the current market conditions provide an attractive entry point for investors, following the pull-in post-BROADWAY.
The firm’s positive outlook on NewAmsterdam is further supported by the company’s strong funding position, which they believe mitigates financial risk and supports the ongoing development of obicetrapib. This assessment is backed by InvestingPro metrics showing an impressive current ratio of 19.98 and minimal debt exposure. The company’s Financial Health Score of 2.38 indicates fair overall condition, with detailed analysis available in the comprehensive Pro Research Report covering this $2.27 billion market cap company. Stifel’s report suggests that the combination of NewAmsterdam’s promising drug candidate, capable leadership, and solid financial foundation positions the company well for future success and possible mergers and acquisitions activity.
Stifel’s initiation of coverage on NewAmsterdam with a Buy rating and a $44 price target reflects their confidence in the company’s potential to outperform within the pharmaceutical industry, particularly in the cardiovascular sector. With a beta of -0.02, the stock has shown limited correlation with market movements, while maintaining strong liquidity metrics. According to InvestingPro’s Fair Value analysis, the stock appears to be trading near its fair value, making it an interesting watch for investors seeking detailed insights through the platform’s extensive company research capabilities.
In other recent news, NewAmsterdam Pharma has reported positive outcomes from a sub-study within its Phase 3 BROADWAY trial, demonstrating significant reductions in Alzheimer’s disease biomarkers with its drug obicetrapib. The trial showed statistically significant reductions in the Alzheimer’s biomarker p-tau217, particularly in patients carrying the ApoE4 gene variant. This development suggests a potential preventative approach to Alzheimer’s disease. Additionally, NewAmsterdam Pharma has announced promising results from its BROADWAY and TANDEM Phase 3 studies, where obicetrapib significantly lowered low-density lipoprotein cholesterol (LDL-C) levels in cardiovascular disease patients.
Cantor Fitzgerald initiated an Overweight rating for NewAmsterdam Pharma, setting a 12-month price target of $42, driven by the potential of obicetrapib in ongoing cardiovascular trials. Meanwhile, RBC Capital reiterated its Outperform rating with a price target of $38, highlighting the drug’s potential in the LDL lowering market. The company also appointed Adele Gulfo to its Board of Directors, bringing her extensive experience in pharmaceutical commercialization to the team. These developments reflect NewAmsterdam’s ongoing efforts to advance obicetrapib as a treatment for cardiovascular and neurodegenerative diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.